These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1761 related articles for article (PubMed ID: 28758319)

  • 1. Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres.
    Wang EA; Stein JP; Bellavia RJ; Broadwell SR
    Int J Clin Pract; 2017 Nov; 71(11):. PubMed ID: 28758319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
    Vilgrain V; Pereira H; Assenat E; Guiu B; Ilonca AD; Pageaux GP; Sibert A; Bouattour M; Lebtahi R; Allaham W; Barraud H; Laurent V; Mathias E; Bronowicki JP; Tasu JP; Perdrisot R; Silvain C; Gerolami R; Mundler O; Seitz JF; Vidal V; Aubé C; Oberti F; Couturier O; Brenot-Rossi I; Raoul JL; Sarran A; Costentin C; Itti E; Luciani A; Adam R; Lewin M; Samuel D; Ronot M; Dinut A; Castera L; Chatellier G;
    Lancet Oncol; 2017 Dec; 18(12):1624-1636. PubMed ID: 29107679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.
    Abdel-Rahman O; Elsayed Z
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011313. PubMed ID: 31978267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.
    Abdel-Rahman OM; Elsayed Z
    Cochrane Database Syst Rev; 2016 Feb; 2():CD011313. PubMed ID: 26905230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial.
    Vilgrain V; Abdel-Rehim M; Sibert A; Ronot M; Lebtahi R; Castéra L; Chatellier G;
    Trials; 2014 Dec; 15():474. PubMed ID: 25472660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective internal radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation.
    Walton M; Wade R; Claxton L; Sharif-Hurst S; Harden M; Patel J; Rowe I; Hodgson R; Eastwood A
    Health Technol Assess; 2020 Sep; 24(48):1-264. PubMed ID: 33001024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cost analysis of SIR-Spheres yttrium-90 resin microspheres versus tyrosine kinase inhibitors in the treatment of unresectable hepatocellular carcinoma in France, Italy, Spain and the UK.
    Pollock RF; Colaone F; Guardiola L; Shergill S; Brennan VK
    J Med Econ; 2020 Jun; 23(6):593-602. PubMed ID: 32067534
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma.
    Golfieri R; Bilbao JI; Carpanese L; Cianni R; Gasparini D; Ezziddin S; Paprottka PM; Fiore F; Cappelli A; Rodriguez M; Ettorre GM; Saltarelli A; Geatti O; Ahmadzadehfar H; Haug AR; Izzo F; Giampalma E; Sangro B; Pizzi G; Notarianni E; Vit A; Wilhelm K; Jakobs TF; Lastoria S;
    J Hepatol; 2013 Oct; 59(4):753-61. PubMed ID: 23707371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma.
    Ricke J; Klümpen HJ; Amthauer H; Bargellini I; Bartenstein P; de Toni EN; Gasbarrini A; Pech M; Peck-Radosavljevic M; Popovič P; Rosmorduc O; Schott E; Seidensticker M; Verslype C; Sangro B; Malfertheiner P
    J Hepatol; 2019 Dec; 71(6):1164-1174. PubMed ID: 31421157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transarterial Radioembolization Versus Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma: A Matching-Adjusted Indirect Comparison of Time to Deterioration in Quality of Life.
    Agirrezabal I; Brennan VK; Colaone F; Shergill S; Pereira H; Chatellier G; Vilgrain V
    Adv Ther; 2022 May; 39(5):2035-2051. PubMed ID: 35279814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma.
    Kolligs FT; Bilbao JI; Jakobs T; Iñarrairaegui M; Nagel JM; Rodriguez M; Haug A; D'Avola D; op den Winkel M; Martinez-Cuesta A; Trumm C; Benito A; Tatsch K; Zech CJ; Hoffmann RT; Sangro B
    Liver Int; 2015 Jun; 35(6):1715-21. PubMed ID: 25443863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial.
    Gandhi M; Choo SP; Thng CH; Tan SB; Low AS; Cheow PC; Goh AS; Tay KH; Lo RH; Goh BK; Wong JS; Ng DC; Soo KC; Liew WM; Chow PK;
    BMC Cancer; 2016 Nov; 16(1):856. PubMed ID: 27821083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of selective internal radiation therapy with Y-90 resin microspheres for intermediate- and advanced-stage hepatocellular carcinoma in Brazil.
    Agirrezabal I; Pereira Grillo Junior LS; Nasser F; Brennan VK; Bugano D; Galastri FL; da-Silva ALFA; Shergill S; da Motta-Leal-Filho JM
    J Med Econ; 2023; 26(1):731-741. PubMed ID: 37139828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NEMESIS: Noninferiority, Individual-Patient Metaanalysis of Selective Internal Radiation Therapy with
    Venerito M; Pech M; Canbay A; Donghia R; Guerra V; Chatellier G; Pereira H; Gandhi M; Malfertheiner P; Chow PKH; Vilgrain V; Ricke J; Leandro G
    J Nucl Med; 2020 Dec; 61(12):1736-1742. PubMed ID: 32358087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Yttrium 90 microspheres for the treatment of hepatocellular carcinoma.
    Memon K; Lewandowski RJ; Riaz A; Salem R
    Recent Results Cancer Res; 2013; 190():207-24. PubMed ID: 22941023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A systematic literature review and network meta-analysis of first-line treatments for unresectable hepatocellular carcinoma based on data from randomized controlled trials.
    Pollock RF; Brennan VK; Shergill S; Colaone F
    Expert Rev Anticancer Ther; 2021 Mar; 21(3):341-349. PubMed ID: 33131346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Yttrium-90 Selective Internal Radiation Therapy with Glass Microspheres for Hepatocellular Carcinoma: Current and Updated Literature Review.
    Lee EW; Alanis L; Cho SK; Saab S
    Korean J Radiol; 2016; 17(4):472-88. PubMed ID: 27390539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Efficacy of Transarterial Radioembolisation in Patients with Intermediate or Advanced Stage Hepatocellular Carcinoma Refractory to Chemoembolisation.
    Klompenhouwer EG; Dresen RC; Verslype C; Laenen A; De Hertogh G; Deroose CM; Bonne L; Vandevaveye V; Maleux G
    Cardiovasc Intervent Radiol; 2017 Dec; 40(12):1882-1890. PubMed ID: 28685382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resin Versus Glass Microspheres for
    Van Der Gucht A; Jreige M; Denys A; Blanc-Durand P; Boubaker A; Pomoni A; Mitsakis P; Silva-Monteiro M; Gnesin S; Lalonde MN; Duran R; Prior JO; Schaefer N
    J Nucl Med; 2017 Aug; 58(8):1334-1340. PubMed ID: 28082436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current role of selective internal irradiation with yttrium-90 microspheres in the management of hepatocellular carcinoma: a systematic review.
    Lau WY; Lai EC; Leung TW
    Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):460-7. PubMed ID: 20888138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 89.